Benzodiazepine Choice and Polydrug Use
苯二氮卓类药物的选择和多种药物的使用
基本信息
- 批准号:10444445
- 负责人:
- 金额:$ 55.58万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-04-01 至 2027-01-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdultAffectAlprazolamAnimalsAnxiety DisordersAttenuatedBenzodiazepinesClinical DataCocaineDangerousnessDataDevelopmentDrug ModelingsDrug usageExhibitsExposure toFoodGABA ModulatorsGeneral PopulationGoalsHeroinIndividualKnowledgeLigandsMacaca mulattaModelingMonkeysOpioidOverdosePatternPharmaceutical PreparationsPharmacologyProceduresPsychological reinforcementRecording of previous eventsReportingResearchRiskRoleSafetySelf AdministrationSleep DisordersStimulantSubstance Use DisorderTestingTherapeuticToxic effectTrainingabuse liabilityaddictionbenzodiazepine abusebenzodiazepine misusedrug of abuseepidemiologic dataexperienceexperimental studyimprovedmultiple drug usenon-drugnovel strategiesoverdose deathpositive allosteric modulatorpreclinical evaluationpredict clinical outcomeprogramsreceptorside effecttherapeutic development
项目摘要
Project Summary
Benzodiazepines (BZs) are effective and safe when used appropriately, but their utility is limited by unwanted
side effects like misuse and reduced safety when combined with other drugs. Individuals with substance-use
disorders (SUDs) misuse BZs as much as 20x greater than the general population, and the rising number of
overdose deaths attributed to BZs are largely driven by opioid co-administration. Given the high rates of polydrug
use among individuals who also misuse BZs, preclinical evaluations of BZs should consider the polydrug
scenarios in which they are being misused. The goal of this research is to identify pharmacological determinants
of BZ misuse, with the goal of identifying BZ-type ligands with reduced abuse potential in polydrug situations.
We reported previously that nonselective, partial-efficacy BZ ligands or those that lack intrinsic efficacy at a1-
subunit containing GABAA (a1GABAA) receptors have reduced abuse potential relative to traditional BZs.
However, our data suggest that the degree to which these BZ-type ligands exhibit abuse potential depends on
the subject’s drug history. This new application will use choice models to evaluate the overall hypothesis that
drug experience is a key determinant of the role of GABAA receptor subtypes in the abuse potential of BZ-type
ligands. A key finding from our choice research is that efficacy at a1GABAA receptors may be necessary for self-
administration of BZs in cocaine-experienced subjects, but not required for enhancement of cocaine choice. It is
unknown whether this pattern of effects is observed with other drugs of abuse, in particular opioids. Moreover,
the pharmacological mechanism underlying these effects is unknown, with possibilities including (1) a differential
role for a1GABAA receptors in reinforcement-enhancing vs. reinforcing effects of BZs alone, or (2) differences in
overall intrinsic efficacy, irrespective of subtype selectivity. We will address these potential mechanisms in two
Aims organized by unique approaches. In Aim 1, we will use drug vs. drug choice to evaluate the extent to which
BZ-type ligands varying in efficacy and selectivity will enhance or attenuate drug choice when delivered as a
combination with cocaine, heroin, or alprazolam in separate groups of subjects. In Aim 2, we will use drug vs.
nondrug choice to evaluate the hypothesis that nonselective, partial modulators or a1-sparing BZs will have
reduced reinforcing effects when delivered alone in subjects with a history of cocaine, heroin, alprazolam, or
food choice. A significant addition to our groups of monkeys with different reinforcement histories will be the
food-experienced animals, providing a quantitative model of drug-naïve individuals’ initial exposure to drug
taking. BZ use among individuals with a SUD, in or out of treatment, is increasingly common and is associated
with increased risk of BZ misuse and overdose. Testing the hypotheses proposed will provide critical information
for understanding how past and current drug use affects the abuse liability of BZ-type drugs.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sally Huskinson其他文献
Sally Huskinson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sally Huskinson', 18)}}的其他基金
Unpredictable availability as a determinant of drug-related outcomes
不可预测的可用性是药物相关结果的决定因素
- 批准号:
10360602 - 财政年份:2018
- 资助金额:
$ 55.58万 - 项目类别:
Unpredictable drug and non-drug alternatives as determinants of cocaine choice
不可预测的药物和非药物替代品是可卡因选择的决定因素
- 批准号:
9097673 - 财政年份:2014
- 资助金额:
$ 55.58万 - 项目类别:
Unpredictable drug and non-drug alternatives as determinants of cocaine choice
不可预测的药物和非药物替代品是可卡因选择的决定因素
- 批准号:
8832401 - 财政年份:2014
- 资助金额:
$ 55.58万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 55.58万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 55.58万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 55.58万 - 项目类别:
Standard Grant
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 55.58万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 55.58万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 55.58万 - 项目类别:
Discovery Early Career Researcher Award
RUI: Evaluation of Neurotrophic-Like properties of Spaetzle-Toll Signaling in the Developing and Adult Cricket CNS
RUI:评估发育中和成年蟋蟀中枢神经系统中 Spaetzle-Toll 信号传导的神经营养样特性
- 批准号:
2230829 - 财政年份:2023
- 资助金额:
$ 55.58万 - 项目类别:
Standard Grant
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 55.58万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 55.58万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 55.58万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




